HLSE:BONEH

Stock Analysis Report

BBS-Bioactive Bone Substitutes Oyj

Executive Summary

BBS-Bioactive Bone Substitutes Oyj develops, designs, manufactures, and sells bioactive bone-graft substitute implants in Finland.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has BBS-Bioactive Bone Substitutes Oyj's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BONEH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

140.8%

BONEH

1.8%

FI Biotechs

-1.9%

FI Market


1 Year Return

161.4%

BONEH

39.1%

FI Biotechs

9.8%

FI Market

Return vs Industry: BONEH exceeded the Finnish Biotechs industry which returned 39.1% over the past year.

Return vs Market: BONEH exceeded the Finnish Market which returned 9.8% over the past year.


Shareholder returns

BONEHIndustryMarket
7 Day140.8%1.8%-1.9%
30 Day139.5%6.7%1.6%
90 Day315.9%18.6%8.7%
1 Year161.4%161.4%39.8%39.1%14.8%9.8%
3 Yearn/a43.7%41.2%33.6%17.6%
5 Yearn/a75.6%75.3%44.6%17.3%

Price Volatility Vs. Market

How volatile is BBS-Bioactive Bone Substitutes Oyj's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BBS-Bioactive Bone Substitutes Oyj undervalued compared to its fair value and its price relative to the market?

13.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BONEH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BONEH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BONEH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BONEH is unprofitable, so we can't compare its PE Ratio to the Finnish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BONEH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BONEH is overvalued based on its PB Ratio (13.1x) compared to the XE Biotechs industry average (4x).


Next Steps

Future Growth

How is BBS-Bioactive Bone Substitutes Oyj forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BBS-Bioactive Bone Substitutes Oyj has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BBS-Bioactive Bone Substitutes Oyj performed over the past 5 years?

-12.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BONEH is currently unprofitable.

Growing Profit Margin: BONEH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BONEH is unprofitable, and losses have increased over the past 5 years at a rate of -12.8% per year.

Accelerating Growth: Unable to compare BONEH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BONEH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: BONEH has a negative Return on Equity (-42.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BBS-Bioactive Bone Substitutes Oyj's financial position?


Financial Position Analysis

Short Term Liabilities: BONEH's short term assets (€1.0M) do not cover its short term liabilities (€1.4M).

Long Term Liabilities: BONEH's short term assets (€1.0M) do not cover its long term liabilities (€5.4M).


Debt to Equity History and Analysis

Debt Level: BONEH's debt to equity ratio (177.9%) is considered high.

Reducing Debt: Insufficient data to determine if BONEH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: BONEH has a low level of unsold assets or inventory.

Debt Coverage by Assets: BONEH's debt is not covered by short term assets (assets are 0.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BONEH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BONEH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.7% each year


Next Steps

Dividend

What is BBS-Bioactive Bone Substitutes Oyj's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.1%markettop25%4.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BONEH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BONEH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BONEH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BONEH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BONEH's dividend in 3 years as they are not forecast to pay a notable one for the Finnish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Ilkka Kangasniemi (55yo)

0.3yrs

Tenure

0

Mr. Ilkka Kangasniemi, Ph.D., Ass. Prof., is the Chief Executive Officer at BBS-Bioactive Bone Substitutes Oyj since October 15, 2019. Mr. Kangasniemi served as Chief Scientific Officer of Vivoxid Ltd. He  ...


Leadership Team

NamePositionTenureCompensationOwnership
Ilkka Kangasniemi
CEO & Director0.3yrsno datano data
Hannu Säynäjäkangas
CFO & Director8.1yrsno datano data
Hanna Tölli
Production Manager & HR Manager0yrsno datano data
Pekka Jalovaara
Adviser & Director17.1yrsno datano data
Paul Watkins
Chief Commercial Officer & Member of Advisory Board0yrsno datano data

0.3yrs

Average Tenure

60yo

Average Age

Experienced Management: BONEH's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ilkka Kangasniemi
CEO & Director0.3yrsno datano data
Hannu Säynäjäkangas
CFO & Director8.1yrsno datano data
Pekka Jalovaara
Adviser & Director17.1yrsno datano data
Paul Watkins
Chief Commercial Officer & Member of Advisory Board0yrsno datano data
Auvo Kaikkonen
Director2.9yrsno datano data
Jarmo Halonen
Chairman of the Board0yrsno datano data
Kirk Andriano
Member of Advisory Board0yrsno datano data
Tomi Numminen
Director1.9yrsno datano data
Brent Atkinsson
Member of Advisory Board0yrsno datano data
Declan Flaherty
Member of Advisory Board0yrsno datano data

2.9yrs

Average Tenure

65yo

Average Age

Experienced Board: BONEH's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Top Shareholders

Company Information

BBS-Bioactive Bone Substitutes Oyj's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BBS-Bioactive Bone Substitutes Oyj
  • Ticker: BONEH
  • Exchange: HLSE
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €47.624m
  • Shares outstanding: 5.20m
  • Website: https://www.bbs-artebone.fi

Number of Employees


Location

  • BBS-Bioactive Bone Substitutes Oyj
  • Kiviharjunlenkki 6
  • Oulu
  • Northern Ostrobothnia
  • 90220
  • Finland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BONESOM (OMX Nordic Exchange Stockholm)YesRegistered SharesSESEKFeb 2018
BONEHHLSE (OMX Nordic Exchange Helsinki)YesRegistered SharesFIEURFeb 2018

Biography

BBS-Bioactive Bone Substitutes Oyj develops, designs, manufactures, and sells bioactive bone-graft substitute implants in Finland. The company offers ARTEBON, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins. BBS-Bioactive Bone Substitutes Oyj was founded in 2003 and is headquartered in Oulu, Finland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 00:10
End of Day Share Price2020/02/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.